|
Lineage Cell Therapeutics, Inc. (LCTX) DCF Valuation
US | Healthcare | Biotechnology | AMEX
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Lineage Cell Therapeutics, Inc. (LCTX) Bundle
Designed for accuracy, our Lineage Cell Therapeutics, Inc. (LCTX) DCF Calculator enables you to evaluate the valuation of Lineage Cell Therapeutics using real-world financial data, offering complete flexibility to modify all essential parameters for improved projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.5 | .8 | 3.9 | 14.7 | 8.9 | 11.5 | 14.7 | 18.9 | 24.2 | 31.1 |
| Revenue Growth, % | 0 | -47.7 | 404.01 | 277.39 | -39.16 | 28.28 | 28.28 | 28.28 | 28.28 | 28.28 |
| EBITDA | -38.9 | -24.4 | -48.3 | -21.8 | -24.0 | -11.5 | -14.7 | -18.9 | -24.2 | -31.1 |
| EBITDA, % | -2630.31 | -3157.57 | -1240.71 | -148.22 | -268.76 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 3.1 | 2.1 | .9 | .7 | .7 | 5.4 | 6.9 | 8.9 | 11.4 | 14.6 |
| Depreciation, % | 211.71 | 273.09 | 22.77 | 4.94 | 7.74 | 47.09 | 47.09 | 47.09 | 47.09 | 47.09 |
| EBIT | -42.0 | -26.5 | -49.2 | -22.5 | -24.7 | -11.5 | -14.7 | -18.9 | -24.2 | -31.1 |
| EBIT, % | -2842.02 | -3430.66 | -1263.48 | -153.17 | -276.5 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 30.7 | 41.6 | 58.4 | 57.9 | 35.5 | 11.5 | 14.7 | 18.9 | 24.2 | 31.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 23.9 | .0 | 50.8 | .3 | .7 | 4.8 | 6.2 | 8.0 | 10.2 | 13.1 |
| Account Receivables, % | 1619.76 | 0.51746 | 1304.93 | 2.02 | 8.33 | 42.17 | 42.17 | 42.17 | 42.17 | 42.17 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0.000067658999 | 0 | 0 | 0.000006801333 | 0 | 0.000014892066 | 0.000014892066 | 0.000014892066 | 0.000014892066 | 0.000014892066 |
| Accounts Payable | 2.4 | 2.6 | 3.5 | 2.4 | 2.0 | 7.6 | 9.7 | 12.5 | 16.0 | 20.5 |
| Accounts Payable, % | 164.21 | 337.77 | 90.94 | 16.28 | 22.92 | 66.03 | 66.03 | 66.03 | 66.03 | 66.03 |
| Capital Expenditure | -.4 | -.1 | -.4 | -.4 | -.7 | -1.3 | -1.7 | -2.2 | -2.8 | -3.6 |
| Capital Expenditure, % | -29.77 | -8.28 | -9.09 | -2.81 | -7.53 | -11.5 | -11.5 | -11.5 | -11.5 | -11.5 |
| Tax Rate, % | 7.71 | 7.71 | 7.71 | 7.71 | 7.71 | 7.71 | 7.71 | 7.71 | 7.71 | 7.71 |
| EBITAT | -25.8 | -25.0 | -43.9 | -23.0 | -22.8 | -10.0 | -12.9 | -16.5 | -21.2 | -27.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -44.7 | 1.1 | -93.2 | 26.7 | -23.6 | -4.5 | -6.9 | -8.8 | -11.3 | -14.5 |
| WACC, % | 10.24 | 10.29 | 10.28 | 10.3 | 10.29 | 10.28 | 10.28 | 10.28 | 10.28 | 10.28 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -32.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -15 | |||||||||
| Terminal Value | -178 | |||||||||
| Present Terminal Value | -109 | |||||||||
| Enterprise Value | -142 | |||||||||
| Net Debt | -32 | |||||||||
| Equity Value | -110 | |||||||||
| Diluted Shares Outstanding, MM | 173 | |||||||||
| Equity Value Per Share | -0.64 |
What You Will Get
- Real LCTX Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Automated Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Explore various scenarios to assess Lineage Cell Therapeutics' future performance.
- User-Friendly Design: Designed for experts while remaining approachable for newcomers.
Key Features
- Comprehensive Financial Data: Gain access to precise pre-loaded historical information and future forecasts for Lineage Cell Therapeutics, Inc. (LCTX).
- Adjustable Forecast Parameters: Modify highlighted fields such as discount rates, growth expectations, and profit margins.
- Real-Time Calculations: Automatic adjustments to discounted cash flow (DCF), Net Present Value (NPV), and cash flow evaluations.
- Interactive Dashboard: User-friendly charts and summaries to help visualize your valuation findings.
- Designed for All Users: A straightforward, intuitive layout tailored for investors, CFOs, and consultants alike.
How It Works
- Download the Template: Gain immediate access to the Excel-based LCTX DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other parameters.
- Instant Calculations: The model automatically recalculates Lineage Cell Therapeutics’ intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the outcomes to inform your investment or financial strategy.
Why Choose This Calculator for Lineage Cell Therapeutics, Inc. (LCTX)?
- Designed for Experts: A sophisticated tool tailored for researchers, investors, and biotech analysts.
- Comprehensive Data: Lineage's historical and projected financials are preloaded for precise analysis.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Insightful Results: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Detailed step-by-step instructions facilitate a smooth experience.
Who Should Use This Product?
- Healthcare Researchers: Explore innovative cell therapies and their applications using real-world data.
- Academics: Integrate cutting-edge research models into your studies or publications.
- Investors: Validate your investment strategies and evaluate the market potential of Lineage Cell Therapeutics (LCTX).
- Analysts: Enhance your analysis with a customizable financial model tailored for biotech firms.
- Biotech Entrepreneurs: Understand how established companies like Lineage Cell Therapeutics (LCTX) navigate the industry landscape.
What the Template Contains
- Historical Data: Includes Lineage Cell Therapeutics, Inc.'s (LCTX) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Lineage Cell Therapeutics, Inc.'s (LCTX) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Lineage Cell Therapeutics, Inc.'s (LCTX) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.